Personalized cell therapy for Parkinson's disease using patient-derived stem cells
Human iPSC-Based Personalized Cell Therapy of PD
This study is working on a special treatment for Parkinson's disease using personalized cells made from your own stem cells, aiming to replace the brain cells that help with movement and improve your symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mclean Hospital NIH-funded |
| Lab location | 1 site (Belmont, United States) |
| Project ID | NIH-11072052 on NIH RePORTER |
What this research studies
This research focuses on developing a personalized cell therapy for Parkinson's disease (PD) by utilizing human induced pluripotent stem cells (hiPSCs) derived from patients. The approach aims to replace lost midbrain dopamine neurons, which are crucial for motor function, by creating tailored cell treatments that match individual genetic backgrounds. The research involves advanced techniques to ensure the safety and effectiveness of these cells, including eliminating undifferentiated cells that could lead to tumors. By addressing the unique needs of each patient, this therapy could potentially halt or reverse the progression of PD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are diagnosed with Parkinson's disease.
Not a fit: Patients with Parkinson's disease who are younger than 65 or those with other neurodegenerative disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that may halt or even reverse the progression of Parkinson's disease.
How similar studies have performed: Previous research has shown promise in using stem cell therapies for neurodegenerative diseases, indicating a potential for success in this novel approach.
Where this research is happening
Belmont, United States
- Mclean Hospital — Belmont, United States (Active)
Researchers
- Principal investigator: Kim, Kwang-Soo — Mclean Hospital
- Study coordinator: Kim, Kwang-Soo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.